{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T20:25:32Z","timestamp":1772310332456,"version":"3.50.1"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:00:00Z","timestamp":1488326400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"DFG","doi-asserted-by":"publisher","award":["MA2530\/6-1"],"award-info":[{"award-number":["MA2530\/6-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"DFG","doi-asserted-by":"publisher","award":["MA2530\/8-1"],"award-info":[{"award-number":["MA2530\/8-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008672","name":"Wilhelm Sander-Stiftung","doi-asserted-by":"crossref","award":["#2014.092.1"],"award-info":[{"award-number":["#2014.092.1"]}],"id":[{"id":"10.13039\/100008672","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100005972","name":"Deutsche Krebshilfe","doi-asserted-by":"crossref","award":["#111853"],"award-info":[{"award-number":["#111853"]}],"id":[{"id":"10.13039\/501100005972","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1016\/j.ejca.2016.12.004","type":"journal-article","created":{"date-parts":[[2017,1,9]],"date-time":"2017-01-09T12:16:33Z","timestamp":1483964193000},"page":"9-21","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"special_numbering":"C","title":["Receptor tyrosine kinase inhibition by regorafenib\/sorafenib inhibits growth and invasion of meningioma cells"],"prefix":"10.1016","volume":"73","author":[{"given":"Marcus","family":"Tuchen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annette","family":"Wilisch-Neumann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evelyn A.","family":"Daniel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Baldauf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Doreen","family":"Pachow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johannes","family":"Scholz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"Angenstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oliver","family":"Stork","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elmar","family":"Kirches","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Mawrin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2016.12.004_bib1","doi-asserted-by":"crossref","first-page":"iv1","DOI":"10.1093\/neuonc\/nov189","article-title":"CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2008\u20132012","volume":"17","author":"Ostrom","year":"2015","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.ejca.2016.12.004_bib2","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s11060-010-0342-2","article-title":"Pathological classification and molecular genetics of meningiomas","volume":"99","author":"Mawrin","year":"2010","journal-title":"J Neurooncol"},{"key":"10.1016\/j.ejca.2016.12.004_bib3","doi-asserted-by":"crossref","first-page":"4250","DOI":"10.1128\/MCB.01581-08","article-title":"NF2\/merlin is a novel negative regulator of mTOR complex 1, and activation of mTORC1 is associated with meningioma and schwannoma growth","volume":"29","author":"James","year":"2009","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.ejca.2016.12.004_bib4","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1038\/ng0294-180","article-title":"Evidence for the complete inactivation of the NF2 gene in the majority of sporadic meningiomas","volume":"6","author":"Ruttledge","year":"1994","journal-title":"Nat Genet"},{"key":"10.1016\/j.ejca.2016.12.004_bib5","doi-asserted-by":"crossref","first-page":"e106","DOI":"10.14694\/EdBook_AM.2015.35.e106","article-title":"Biology and clinical management challenges in meningioma","author":"Mawrin","year":"2015","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.ejca.2016.12.004_bib6","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1007\/s00401-013-1187-5","article-title":"AKT1E17K mutations cluster with meningothelial and transitional meningiomas and can be detected by SFRP1 immunohistochemistry","volume":"126","author":"Sahm","year":"2013","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.ejca.2016.12.004_bib7","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1126\/science.1233009","article-title":"Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO","volume":"339","author":"Clark","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.ejca.2016.12.004_bib8","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/ng.2526","article-title":"Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations","volume":"45","author":"Brastianos","year":"2013","journal-title":"Nat Genet"},{"key":"10.1016\/j.ejca.2016.12.004_bib9","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s11060-011-0541-5","article-title":"Hydroxyurea for recurrent surgery and radiation refractory meningioma: a retrospective case series","volume":"104","author":"Chamberlain","year":"2011","journal-title":"J Neurooncol"},{"key":"10.1016\/j.ejca.2016.12.004_bib10","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1016\/j.ejca.2012.01.032","article-title":"Sunitinib targets PDGF-receptor and Flt3 and reduces survival and migration of human meningioma cells","volume":"48","author":"Andrae","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2016.12.004_bib11","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1093\/neuonc\/nou148","article-title":"Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma","volume":"17","author":"Kaley","year":"2015","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.ejca.2016.12.004_bib12","doi-asserted-by":"crossref","first-page":"4074","DOI":"10.1158\/1078-0432.CCR-04-2550","article-title":"Different activation of mitogen-activated protein kinase and Akt signaling is associated with aggressive phenotype of human meningiomas","volume":"11","author":"Mawrin","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2016.12.004_bib13","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1097\/01.jnen.0000189834.63951.81","article-title":"Mitogenic signal transduction pathways in meningiomas: novel targets for meningioma chemotherapy?","volume":"64","author":"Johnson","year":"2005","journal-title":"J Neuropathol Exp Neurol"},{"key":"10.1016\/j.ejca.2016.12.004_bib14","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.jocn.2014.10.030","article-title":"MKP-3 regulates PDGF-BB effects and MAPK activation in meningioma cells","volume":"22","author":"Johnson","year":"2015","journal-title":"J Clin Neurosci"},{"key":"10.1016\/j.ejca.2016.12.004_bib15","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1111\/j.1365-2990.1994.tb00994.x","article-title":"Platelet-derived growth factor (PDGF) and receptor (PDGFR) expression in human meningiomas: correlations with clinicopathological features and cytogenetic analysis","volume":"20","author":"Figarella-Branger","year":"1994","journal-title":"Neuropathol Appl Neurobiol"},{"key":"10.1016\/j.ejca.2016.12.004_bib16","doi-asserted-by":"crossref","first-page":"32713","DOI":"10.18632\/oncotarget.5296","article-title":"PDGF activation in PGDS-positive arachnoid cells induces meningioma formation in mice promoting tumor progression in combination with Nf2 and Cdkn2ab loss","volume":"6","author":"Peyre","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejca.2016.12.004_bib17","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1517\/14656566.2012.654776","article-title":"Sorafenib for the treatment of renal cancer","volume":"13","author":"Strumberg","year":"2012","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.ejca.2016.12.004_bib18","doi-asserted-by":"crossref","first-page":"7099","DOI":"10.1158\/0008-5472.CAN-04-1443","article-title":"BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF\/MEK\/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis","volume":"64","author":"Wilhelm","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2016.12.004_bib19","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.yexcr.2014.10.018","article-title":"Anti-tumor activity of sorafenib in a model of a pediatric hepatocellular carcinoma","volume":"331","author":"Nagel","year":"2015","journal-title":"Exp Cell Res"},{"key":"10.1016\/j.ejca.2016.12.004_bib20","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/ijc.25864","article-title":"Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity","volume":"129","author":"Wilhelm","year":"2011","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ejca.2016.12.004_bib21","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1517\/13543784.2012.684752","article-title":"Regorafenib for cancer","volume":"21","author":"Strumberg","year":"2012","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.ejca.2016.12.004_bib22","first-page":"81","article-title":"Regorafenib: an evidence-based review of its potential in patients with advanced liver cancer","volume":"9","author":"Ravi","year":"2014","journal-title":"Core Evid"},{"key":"10.1016\/j.ejca.2016.12.004_bib23","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1517\/13543784.2015.1070483","article-title":"An overview of experimental and investigational multikinase inhibitors for the treatment of metastatic colorectal cancer","volume":"24","author":"Lee","year":"2015","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.ejca.2016.12.004_bib24","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.surneu.2007.06.031","article-title":"A comparison of the cell lines used in meningioma research","volume":"70","author":"Ragel","year":"2008","journal-title":"Surg Neurol"},{"key":"10.1016\/j.ejca.2016.12.004_bib25","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1227\/00006123-199009000-00008","article-title":"Characterization of a newly established malignant meningioma cell line of the human brain: IOMM-Lee","volume":"27","author":"Lee","year":"1990","journal-title":"Neurosurgery"},{"key":"10.1016\/j.ejca.2016.12.004_bib26","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1007\/s00432-014-1683-6","article-title":"Re-evaluation of cytostatic therapies for meningiomas in\u00a0vitro","volume":"140","author":"Wilisch-Neumann","year":"2014","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.ejca.2016.12.004_bib27","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1158\/1078-0432.CCR-12-1904","article-title":"mTORC1 inhibitors suppress meningioma growth in mouse models","volume":"19","author":"Pachow","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2016.12.004_bib28","doi-asserted-by":"crossref","first-page":"5402","DOI":"10.1158\/1078-0432.CCR-12-0299","article-title":"The integrin inhibitor cilengitide affects meningioma cell motility and invasion","volume":"19","author":"Wilisch-Neumann","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2016.12.004_bib29","doi-asserted-by":"crossref","first-page":"5099","DOI":"10.1158\/0008-5472.CAN-08-4475","article-title":"Human schwannomas express activated platelet-derived growth factor receptors and c-kit and are growth inhibited by Gleevec (Imatinib Mesylate)","volume":"69","author":"Mukherjee","year":"2009","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2016.12.004_bib30","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1093\/neuonc\/not330","article-title":"Historical benchmarks for medical therapy trials in surgery- and radiation-refractory meningioma a RANO review","volume":"16","author":"Kaley","year":"2014","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.ejca.2016.12.004_bib31","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1007\/s11060-009-9948-7","article-title":"Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma","volume":"96","author":"Norden","year":"2009","journal-title":"J Neurooncol"},{"key":"10.1016\/j.ejca.2016.12.004_bib32","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/ijc.2910460106","article-title":"Human meningiomas co-express platelet-derived growth factor (PDGF) and PDGF-receptor genes and their protein products","volume":"46","author":"Maxwell","year":"1990","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ejca.2016.12.004_bib33","doi-asserted-by":"crossref","first-page":"388","DOI":"10.3171\/jns.1994.81.3.0388","article-title":"Platelet-derived growth factor expression and stimulation in human meningiomas","volume":"81","author":"Black","year":"1994","journal-title":"J Neurosurg"},{"issue":"Suppl. 1","key":"10.1016\/j.ejca.2016.12.004_bib34","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1054\/jocn.2001.0877","article-title":"Expression of PDGF and its receptor as well as their relationship to proliferating activity and apoptosis of meningiomas in human meningiomas","volume":"8","author":"Yang","year":"2001","journal-title":"J Clin Neurosci"},{"key":"10.1016\/j.ejca.2016.12.004_bib35","doi-asserted-by":"crossref","first-page":"e92146","DOI":"10.1371\/journal.pone.0092146","article-title":"Comparison of the cancer gene targeting and biochemical selectivities of all targeted kinase inhibitors approved for clinical use","volume":"9","author":"Uitdehaag","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.ejca.2016.12.004_bib36","first-page":"50","article-title":"The molecular biology of hormone and growth factor receptors in meningiomas","volume":"65","author":"Black","year":"1996","journal-title":"Acta Neurochir Suppl"},{"key":"10.1016\/j.ejca.2016.12.004_bib37","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1111\/neup.12266","article-title":"Activation of multiple growth factor signalling pathways is frequent in meningiomas","volume":"36","author":"Hilton","year":"2016","journal-title":"Neuropathology"},{"key":"10.1016\/j.ejca.2016.12.004_bib38","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/clpt.2012.96","article-title":"Pharmacogenomics knowledge for personalized medicine","volume":"92","author":"Whirl-Carrillo","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.ejca.2016.12.004_bib39","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.ejca.2016.04.019","article-title":"Effects of the multikinase inhibitors sorafenib and regorafenib in PTEN deficient neoplasias","volume":"63","author":"Mirantes","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2016.12.004_bib40","doi-asserted-by":"crossref","first-page":"3729","DOI":"10.2174\/138161211798220918","article-title":"Cytokine signaling modulates blood-brain barrier function","volume":"17","author":"Pan","year":"2011","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.ejca.2016.12.004_bib41","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1042\/BST20140319","article-title":"The blood\u2013brain barrier endothelium: a target for pro-inflammatory cytokines","volume":"43","author":"Rochfort Keith","year":"2015","journal-title":"Biochem Soc Trans"},{"key":"10.1016\/j.ejca.2016.12.004_bib42","doi-asserted-by":"crossref","first-page":"5236","DOI":"10.1158\/0008-5472.CAN-07-5849","article-title":"Dissecting and targeting the growth factor-dependent and growth factor-independent extracellular signal-regulated kinase pathway in human schwannoma","volume":"68","author":"Ammoun","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2016.12.004_bib43","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1093\/neuonc\/nou059","article-title":"Phase II study of sorafenib in children with recurrent or progressive low-grade astrocytomas","volume":"16","author":"Karajannis","year":"2014","journal-title":"Neuro Oncol"},{"key":"10.1016\/j.ejca.2016.12.004_bib44","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1038\/bjc.2014.209","article-title":"Phase I study of sorafenib combined with radiation therapy and temozolomide as first-line treatment of high-grade glioma","volume":"110","author":"Hottinger","year":"2014","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2016.12.004_bib45","doi-asserted-by":"crossref","first-page":"e0142612","DOI":"10.1371\/journal.pone.0142612","article-title":"Regorafenib: antitumor activity upon mono and combination therapy in preclinical pediatric malignancy models","volume":"10","author":"Daudigeos-Dubus","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.ejca.2016.12.004_bib46","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1227\/01.NEU.0000197104.78684.5D","article-title":"Medial sphenoid wing meningiomas: clinical outcome and recurrence rate","volume":"58","author":"Nakamura","year":"2006","journal-title":"Neurosurgery"},{"key":"10.1016\/j.ejca.2016.12.004_bib47","first-page":"2046","article-title":"\u201cMalignancy\u201d in meningiomas: a clinicopathologic study of 116 patients, with grading implications","volume":"85","author":"Perry","year":"1999","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2016.12.004_bib48","first-page":"1967","article-title":"Sorafenib inhibits migration and invasion of hepatocellular carcinoma cells through suppression of matrix metalloproteinase expression","volume":"35","author":"Ha","year":"2015","journal-title":"Anticancer Res"},{"key":"10.1016\/j.ejca.2016.12.004_bib49","doi-asserted-by":"crossref","first-page":"2809","DOI":"10.1007\/s00726-014-1838-4","article-title":"Metformin inhibits the invasion of human hepatocellular carcinoma cells and enhances the chemosensitivity to sorafenib through a downregulation of the ERK\/JNK-mediated NF-\u03baB-dependent pathway that reduces uPA and MMP-9 expression","volume":"46","author":"Hsieh","year":"2014","journal-title":"Amino Acids"},{"key":"10.1016\/j.ejca.2016.12.004_bib50","doi-asserted-by":"crossref","first-page":"e16","DOI":"10.1111\/nan.12166","article-title":"A role for matrix remodelling proteins in invasive and malignant meningiomas","volume":"41","author":"Jalali","year":"2015","journal-title":"Neuropathol Appl Neurobiol"},{"key":"10.1016\/j.ejca.2016.12.004_bib51","first-page":"26","article-title":"Expression of matrix metalloproteinases in a series of 12 meningiomas","volume":"20","author":"Kirches","year":"2001","journal-title":"Clin Neuropathol"},{"key":"10.1016\/j.ejca.2016.12.004_bib52","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1002\/jcp.24291","article-title":"Effects of low concentrations of regorafenib and sorafenib on human HCC cell AFP, migration, invasion, and growth in\u00a0vitro","volume":"228","author":"Carr","year":"2013","journal-title":"J Cell Physiol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804916330714?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804916330714?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,17]],"date-time":"2019-09-17T08:54:56Z","timestamp":1568710496000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804916330714"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3]]},"references-count":52,"alternative-id":["S0959804916330714"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2016.12.004","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2017,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Receptor tyrosine kinase inhibition by regorafenib\/sorafenib inhibits growth and invasion of meningioma cells","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2016.12.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}